Recently, Dr. Leo Luo joined Ubigene. From 2011 to 2020, Dr. Luo successively completed his Master and PhD degrees in Chinese Academy of Sciences, Guangzhou Institutes of Biomedicine and Health (GIBH), and postdoctoral training in Joint School of Life Sciences, Guangzhou Medical University and Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. During this period, Dr. Luo’s research interests mainly focus on pluripotency regulation mechanism of pluripotent stem cells (PSCs) and its application. He has many years of study experience in stem cell related molecular biology, cell biology, such as the application of genome editing in pluripotent stem cells, molecular mechanisms of somatic cell reprogramming, lineage-specific differentiation of PSCs for disease modeling, etc. The results of his participated researches are published in NATURE CELL BIOLOGY, Stem Cell Reports, CELL RESEARCH and other high-level scientific journals.

Ubigene has been accelerating her plan of the pre-clinical scientific research of stem cell gene editing technology, antibody drug development, and the development and application of gene therapeutic technology for genetic, cancer and other diseases. With the joining of Dr. Luo, Ubigene will accelerate the pace and strive to break through the bottleneck of this field, and act as a practitioner and assistant in drug R & D, pre-clinical research.

CRISPR-U™ and CRISPR-B™, developed by Ubigene, can improve the efficiency of gene editing by 10-30 times, which are breakthrough patented technologies in vivo and vitro. To develop the global market, Ubigene’s services and products radiate over land and sea from China outward to the whole world. Ubigene has provided high-quality products and services to customers in more than 20 countries and 100 regions.